P1.01-53 Clinical Utility of Two Different Plasma-Based EGFR Mutation Tests in Patients with Advanced Non-Small Cell Lung Cancer

When tumor biopsies from patients (pts) with advanced NSCLC yield infeasible or insufficient for successful molecular subtyping, plasma cfDNA genotyping has been widely adopted due to its convenience and high positive predictive value. However, a different assay sensitivity makes the optimal choice more difficult. In this study, we have analyzed the clinical utility of two different plasma-based EGFR-mutation (mEGFR) tests in pts with advanced...